MedPath

ND-YAG Laser Iris Depigmentation for Cosmoses

Not Applicable
Withdrawn
Conditions
Iris Depigmentation
Interventions
Device: Nd-YAG Laser for iris depigmentation
Registration Number
NCT06099041
Lead Sponsor
Sohag University
Brief Summary

Nd-YAG Laser for changing iris coloration by the principle of depigmentation for cosmoses Is that procedure safe or not a prospective study

Detailed Description

Nd-YAG Laser for changing iris coloration by the principle of depigmentation for cosmoses Is that procedure safe or not a prospective study safety will be assessed by measuring IOP using Goldman applanation tonometry pre and post-session.

visual acuity assessment in Log-Mar pre and post-session. Refraction assessment pre and post-session. Lens and fundus assessments on slit-lamp and using auxiliary lens 78D

Recruitment & Eligibility

Status
WITHDRAWN
Sex
All
Target Recruitment
60
Inclusion Criteria
  • clear cornea
  • clear lens
  • normal IOP < 20 mmHg
  • adults aged more than 18 years old
  • normal fundus
  • dark pigmented iris (black or brown)
Exclusion Criteria
  • Glaucomatous patients and those receiving anti-glaucoma treatment.
  • corneal or lens opacity.
  • any fundus abnormality

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
ND-YAG Laser for iris depigmentationNd-YAG Laser for iris depigmentationND-YAG Laser for iris depigmentation
Primary Outcome Measures
NameTimeMethod
Monitoring intra-ocular pressure (IOP) by the standard Goldman applanation tonometer before and after ND-YAG Laser for iris depigmentationone year

Session of Nd-YAG Laser targeting the iris using power less than that used for peripheral iridotomy causing pigment bleaching to change the iris colour for cosmoses, which may cause pigmentary glaucoma (secondary open angle glaucoma).

Safety of ND-YAG Laser, by visual acuity assessment in log-mar subjectively by using Snellen chart before and after ND-YAG Laserone year

If ND-YAG LASER could affect visual acuity.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Elshimaa A.Mateen

🇪🇬

Sohag, Egypt

© Copyright 2025. All Rights Reserved by MedPath